Role of Endothelial Dysfunction Marker along with Toll-like Receptors 4 (TLR-4) Polymorphism in Patients with Type 1 Diabetes Mellitus
DOI:
https://doi.org/10.46966/msjar.v6i3.297Keywords:
E-selectin, TLR-4, Type 1 Diabetes MellitusAbstract
Background: The immune system specifically destroys insulin-producing beta cells in the pancreas in type 1 diabetes mellitus (T1DM), an autoimmune disease. CD4+T cells plan the attack, while CD8+T cells kill the beta cells directly, causing insulin insufficiency and uncontrolled blood sugar levels. Objective: The aim of study is to evaluate E-selectin as a diagnostic biomarker for T1D patients. Additionally, evaluate of TLR-4 polymorphisms by PCR-RFLP. Methodology: Overall, 150 participants were included (75 patients and 75 healthy control) the ages between (10 and 35) years.The serum levels of E-selectin were estimated by ELISA kits. Results: The present study demonstrates that the level of E-selectin was significantly higher in T1D patients compared with controls. As regards the (TLR4) Asp299Gly (rs4986790) genes in patients with polymorphism, In T1DM patients compared with healthy control, the present results show that the genotypes and allele frequencies are significantly (p = 0.001). Conclusion: According to the Receiver operating characteristic (ROC) analysis, in the present results indicates E-Selectin is considered as a weak prognostic marker to distinguish T1DM patients. Additionally, no such correlation was found into the TLR-4 Asp299Gly (rs4986790) polymorphism in patients with T1D.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Ibrahim Abd Ali Abdul Sada Alkinani, Adnan Hamad Aubaid Al-Hamadani
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
